OBJECTIVE: To determine the prevalence and clinical features of pathologically proven incidental cancer (IC) detected by whole-body fluorine-18 fludeoxyglucose ((18)F-FDG) positron emission tomography (PET)/CT, as well as the incidence of false-positive and false-negative results. METHODS: We retrospectively reviewed reports derived from (18)F-FDG PET/CT images of 3079 consecutive patients with known or suspected malignancies for 3 years. Discrete focal uptake indicating IC was identified from reports as well as pathological or clinical diagnoses, and the clinical courses were investigated. The false-positive result was defined as uptake indicating IC but not pathologically confirmed as malignant during follow-up. The false-negative result was defined as pathologically proven IC detected by another modality at initial clinical work-up or diagnosed during the follow-up period. RESULTS: We found (18)F-FDG uptake indicating IC in 6.7% of all patients, and IC was pathologically proven in 2.2% of all patients. The most common sites were the colon, lung and stomach. The median survival duration of patients with IC was 42 months. The results were false positive in 4.5% of all patients, and the results were false negative in 2.3% of all patients. CONCLUSION: (18)F-FDG PET/CT is a valuable tool for detecting IC. The rates of false-positive and false-negative results are within acceptable range. ADVANCES IN KNOWLEDGE: This is the first report to describe the survival of patients with IC, and the detailed features of false-negative results at actual clinical settings.
OBJECTIVE: To determine the prevalence and clinical features of pathologically proven incidental cancer (IC) detected by whole-body fluorine-18 fludeoxyglucose ((18)F-FDG) positron emission tomography (PET)/CT, as well as the incidence of false-positive and false-negative results. METHODS: We retrospectively reviewed reports derived from (18)F-FDG PET/CT images of 3079 consecutive patients with known or suspected malignancies for 3 years. Discrete focal uptake indicating IC was identified from reports as well as pathological or clinical diagnoses, and the clinical courses were investigated. The false-positive result was defined as uptake indicating IC but not pathologically confirmed as malignant during follow-up. The false-negative result was defined as pathologically proven IC detected by another modality at initial clinical work-up or diagnosed during the follow-up period. RESULTS: We found (18)F-FDG uptake indicating IC in 6.7% of all patients, and IC was pathologically proven in 2.2% of all patients. The most common sites were the colon, lung and stomach. The median survival duration of patients with IC was 42 months. The results were false positive in 4.5% of all patients, and the results were false negative in 2.3% of all patients. CONCLUSION: (18)F-FDG PET/CT is a valuable tool for detecting IC. The rates of false-positive and false-negative results are within acceptable range. ADVANCES IN KNOWLEDGE: This is the first report to describe the survival of patients with IC, and the detailed features of false-negative results at actual clinical settings.
Authors: Ora Israel; Nikolay Yefremov; Rachel Bar-Shalom; Olga Kagana; Alex Frenkel; Zohar Keidar; Doron Fischer Journal: J Nucl Med Date: 2005-05 Impact factor: 10.057
Authors: Dimitrios Karantanis; Dimitrios Kalkanis; Martin Allen-Auerbach; Trond Velde Bogsrud; Rathan M Subramaniam; Adam Danielson; Val J Lowe; Johannes Czernin Journal: J Nucl Med Date: 2012-08-23 Impact factor: 10.057
Authors: Jacques Ferlay; Hai-Rim Shin; Freddie Bray; David Forman; Colin Mathers; Donald Maxwell Parkin Journal: Int J Cancer Date: 2010-12-15 Impact factor: 7.396
Authors: Rachel Bar-Shalom; Nikolai Yefremov; Ludmila Guralnik; Diana Gaitini; Alex Frenkel; Abraham Kuten; Hernan Altman; Zohar Keidar; Ora Israel Journal: J Nucl Med Date: 2003-08 Impact factor: 10.057